H Lundbeck (HLUNb)

Currency in DKK
62.65
+0.50(+0.80%)
Real-time Data·
HLUNb is included in our AI-picked strategies. See how they work
Fair Value
Day's Range
61.1562.65
52 wk Range
35.3062.95
Key Statistics
Prev. Close
62.15
Open
62
Day's Range
61.15-62.65
52 wk Range
35.3-62.95
Volume
94.53K
Average Volume (3m)
892.77K
1-Year Change
41.9991%
Book Value / Share
28,50
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
HLUNb Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
58.50
Downside
-6.62%
Members' Sentiments
Bearish
Bullish
ProTips
Has raised its dividend for 4 consecutive years

H Lundbeck News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Analyst Ratings

5 Buy
4 Hold
3 Sell
Ratings:
12 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 58.50
(-6.62% Downside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
UBS
Buy73.00+16.71%53.00MaintainNov 18, 2026
Deutsche Bank
Sell40.00-36.05%36.00MaintainNov 13, 2026
Barclays
Hold60.00-4.08%50.00MaintainNov 12, 2026
UBS
Buy52.00-16.87%45.00UpgradeSep 21, 2026
Deutsche Bank
Sell36.00-42.45%40.00DowngradeSep 15, 2026

Earnings

Latest Release
Nov 10, 2026
EPS / Forecast
1,28 / 1,11
Revenue / Forecast
6,6B / 6,34B
EPS Revisions
Last 90 days

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 4,16
Dividend Yield
1.85%
Industry Median 3.86%
Annualised payout
1.15
Paid annually
5-Years Growth
+18.13%
Growth Streak

HLUNb Income Statement

Compare HLUNb to Peers and Sector

Metrics to compare
HLUNb
Peers
Sector
Relationship
P/E Ratio
14.9x20.6x−0.2x
PEG Ratio
1.400.060.00
Price/Book
2.2x2.8x2.6x
Price / LTM Sales
2.3x3.1x2.7x
Upside (Analyst Target)
−5.9%11.4%69.6%
Fair Value Upside
Unlock12.9%11.7%Unlock

H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression. It also provides Northera for symptomatic neurogenic orthostatic hypotension; Onfi for epilepsy; Sabril for refractory complex partial seizures and infantile spasms; Ebixa for dementia, Azilect for Parkinson’s disease; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol for psychosis. In addition, the company develops Eptinezumab for migraine prevention; Eptinezumab, which is in phase 3 clinical trial for cluster headache; Lu AG09222, which is in phase 2 clinical trial for migraine prevention; Lu AG13909 that is in phase 1 clinical trial for neurohormonal dysfunctions; Brexpiprazole for post-traumatic stress disorder; Lu AF28996, which is in phase 1 clinical trial for Parkinson’s disease; MAGLi program that is in phase 1 clinical trial for neurology; Bexicaserin, which is in phase 3 clinical trial for developmental and epileptic encephalopathies; Amlenetug that is in phase 3 clinical trial for synucleinopathies; and Lu AG22515, which is in clinical phase 1 clinical trial for neurology. Lundbeck A/S has a strategic research collaboration with Contera Pharma to develop oligonucleotide-based medicines for patients living with serious neurological conditions. The company was founded in 1915 and is headquartered in Valby, Denmark.

Employees
5000
Market
Denmark

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
110,70M11,17%6,80B
Other Institutional Investors
686,59M69,27%42,16B
Public Companies & Retail Investors
193,93M19,56%11,91B
Total
991,23M100,00%60,86B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Lundbeckfonden BioCapital69,11%685 069 88442 063 291
Polar Capital Holdings Plc2,14%21 234 0561 303 771

FAQ

What Is the H Lundbeck (HLUNb) Stock Price Today?

The H Lundbeck stock price today is 62,65 DKK.

What Stock Exchange Does H Lundbeck Trade On?

H Lundbeck is listed and trades on the Copenhagen Stock Exchange.

What Is the Stock Symbol for H Lundbeck?

The stock symbol for H Lundbeck is "HLUNb."

Does H Lundbeck Pay Dividends? What’s The Current Dividend Yield?

The H Lundbeck dividend yield is 1,9%%.

What Is the H Lundbeck Market Cap?

As of today, H Lundbeck market cap is 61,26B DKK.

What Is H Lundbeck's Earnings Per Share (TTM)?

The H Lundbeck EPS (TTM) is 4,16.

When Is the Next H Lundbeck Earnings Date?

H Lundbeck will release its next earnings report on Feb 10, 2027.

From a Technical Analysis Perspective, Is HLUNb a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has H Lundbeck Stock Split?

H Lundbeck has split 0 times.

How Many Employees Does H Lundbeck Have?

H Lundbeck has 5000 employees.

What is the current trading status of H Lundbeck (HLUNb)?

As of Nov 19, 2026, H Lundbeck (HLUNb) is trading at a price of 62,65 DKK, with a previous close of 62,15 DKK. The stock has fluctuated within a day range of 61,15 DKK to 62,65 DKK, while its 52-week range spans from 35,30 DKK to 62,95 DKK.

What Is H Lundbeck (HLUNb) Price Target According to Analysts?

The average 12-month price target for H Lundbeck is 58,50 DKK, with a high estimate of 73 DKK and a low estimate of 40 DKK. 5 analysts recommend buying the stock, while 3 suggest selling, leading to an overall rating of Buy. The stock has an -6,62% Downside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.